TECNOTREE
7.8.2024 11:59:35 CEST | Business Wire | Press release
Tecnotree, a global leader in digital platforms and services for AI, 5G, and cloud-native technologies, has been mentioned in three different 2024 Gartner Hype Cycle reports, recently published. Tecnotree has been cited under the categories of Hype Cycle for Enterprise Communication Services, Private Mobile Network Services, and Operations and Automation in Communications Industry, 2024. We believe that these recognitions highlight Tecnotree’s excellence in Partner Ecosystem Management Platforms for CSPs and CSP Digital Marketplaces for Tecnotree Moments Partner Ecosystem Platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807343127/en/
Tecnotree Recognized in 3 Different 2024 Gartner® Hype Cycle™ Reports, for Partner Ecosystem Management Platforms for CSPs, CSP Digital Marketplaces, and AI for CSP Customer Interactions Categories (Graphic: Business Wire)
As per Gartner, “Gartner Hype Cycles provide a graphic representation of the maturity and adoption of technologies and applications, and how they are potentially relevant to solving real business problems and exploiting new opportunities. Gartner Hype Cycle methodology gives you a view of how a technology or application will evolve over time, providing a sound source of insight to manage its deployment within the context of your specific business goals.” Digital marketplaces are an increasingly important part of the CSPs’ go-to-market strategy for digital services and small-and-midsize-business (SMB) and consumer segments. CSPs can enrich their offerings with partner solutions, drive data insights on buyer behavior, and implement automation for faster cycles and improved digital engagement. CSPs can use marketplaces to differentiate from competitors through expanding portfolio with partner offerings, ease-of-use, automation, composable bundles, verticalization and locally tailored offerings.
Tecnotree Moments powered by TM Forum certified Open APIs and Open Digital Architecture (ODA) compliant, provides superior digital experience management operations with advertising and partner led campaign management solutions for aim driven product recommendations, customer journey orchestration, partner management, content and channel personalisation, and dynamic loyalty programs. The Tecnotree Moments multi experience platform using Azure and AWS cloud infrastructure with multitenancy capabilities. The low/no code platform provides intelligence enabled customer experience, based on AI & ML and automation utilizing cloud technologies.
Tecnotree Moments, marketplace accelerates time to market, extends outreach to target segments, expands partner ecosystems, and speeds up the sales cycle. For CSPs, marketplaces target increased self-service and digital engagement, revenue growth, tailored solutions that can be composed based on the needs of each buyer, and actionable data insights on purchase behavior that can inform product developers and enrich the support of ecosystem partners.
Padma Ravichander, CEO, Tecnotree Corporation said, “We are thrilled to be acknowledged in three of the Gartner Hype Cycles. We believe that this recognition underscores our forward-looking vision unwavering commitment to delivering unparalleled value by redefining digital experiences and enhancing revenue monetization capabilities for our customers. Leveraging AI, 5G, and cloud-native technologies, we drive innovation that empowers CSPs with personalized, highly secure solutions. Our inclusion in these reports validates our dedication to pushing the boundaries and continuously expanding our use of AI applications to improve productivity, efficiency, and customer experience.”
Gartner, Hype Cycle for Customer Experience and Monetization in the Communications Industry, 2024, By Susan Welsh de Grimaldo, Pulkit Pandey, 25 July 2024.
Gartner, Hype Cycle for Enterprise Communication Services, 2024, By Khurram Shahzad, 16 July 2024.
Gartner, Hype Cycle for Operations and Automation in the Communications Industry, 2024, By Mounish Rai, Amresh Nandan, 23 July 2024.
Gartner Research Methodologies, Gartner Hype Cycle, August 5, 2024, https://www.gartner.com/en/research/methodologies/gartner-hype-cycle
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807343127/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom